Al Manar International Welfare

Welcome to Al-Manar International Welfare Foundation

At Al-Manar International Welfare Foundation, we are committed to making a difference in people's lives through healthcare, education, and social welfare. Our organization operates as a non-political, non-profit, and voluntary humanitarian foundation, ensuring that every individual has access to essential services, regardless of their financial capabilities. Our services focus on cancer treatment, pediatric and maternal healthcare, critical care, and medical education—ensuring that no one is left behind due to financial barriers.

Vision

Mission

Goal

Opportunity

Education

Autism

Prof. Dr. Sanawar Hossain

Chairman

Specialty - Chief Consultant General Surgery
Degree - MBBS, MD, FCPS, FAMASI

Michael Reney joined Dana-Farber in 2015, and is responsible for treasury, accounting, business planning, revenue cycle, payer contracting, decision support, and population management. He also serves as Assistant Treasurer of multiple Dana-Farber entities.

Prior to joining Dana-Farber, he served as Chief Financial Officer at Brigham and Women’s Hospital (BWH). Mr. Reney began his career as a senior auditor at Deloitte & Touche, LLP, later serving in various financial leadership roles within Partners Healthcare. He was named Senior Vice President for Finance and Chief Financial Officer for BWHC in 2008.

Mr. Reney holds a Bachelor’s in Accounting from Bentley College and a Master’s in Business Administration from the University of Massachusetts, Boston. He is a member of the Healthcare Financial Management Association and serves on several boards.

Details

Professor Dr. Abu Kholdun Al Mahmood

Managing Director

Specialty - Professor & Head of the Department, Al Manar
Degree - MBBS, M Phil, Phd (Malaysia)

Executive Vice President and Chief Operating Officer

William C. Hahn, MD, PhD has been engaged in clinical care and research at Dana-Farber Cancer Institute since 1996. He is the William Rosenberg Professor of Medicine in the Department of Medical Oncology at Dana-Farber and Harvard Medical School, and an Institute Member of the Broad Institute of MIT and Harvard. He serves as an Executive Vice President and the Chief Operating Officer of Dana-Farber.

He received his AB in Biochemical Sciences, PhD in Immunology, and MD — all from Harvard University — and completed his clinical training at Massachusetts General Hospital and Dana-Farber. His research focuses on understanding how mutations cooperate in cancer initiation and progression to develop rational combination therapies.

Dr. Hahn has made numerous discoveries that have informed our current molecular understanding of cancer. His laboratory has pioneered the use of integrated functional genomic approaches to identify and validate cancer targets. He received multiple awards including the Wilson S. Stone Award (2000), the Ho-Am Prize in Medicine (2010), the Richard and Hinda Rosenthal Award (2015), the Claire and Richard Morse Award (2019), and the Hope Funds Award for Excellence in Medicine (2023). He is an elected member of multiple esteemed medical societies.

Details